Swollen gland
Overview
The FDA has approved this medication for schizophrenia if the patient is over the age of 13 and bipolar disorder, including mixed or manic episodes
• Olanzapine may be given without regard to meals (2
4 5-HT 2 receptors have been reported to be involved in controlling sleep quality
g
Main Outcomes and MeasuresPatient-reported outcomes were used for study end points
Olanzapine resulted in hyperinsulinemia and reduced insulin sensitivity during an OGTT at day 19, changes not observed with OLZ/SAM or placebo
Overall, these findings suggest that the addition of an atypical antipsychotic-antimanic agent in some bipolar disorder patients may help to reduce suicidal id
Increased appetite
Without significant memory or concentration problems, agitation, behavioural disturbance or Olanzapine is an atypical antipsychotic currently with indications for the treatment of schizophrenia, acute mania and the prevention of relapse in bipolar disorder